Non categorizzato Novo Nordisk stock drops 18% after obesity drug trial results Dicembre 20, 2024 0 commenti Novo Nordisk shares tumbled by more than 18% on Friday after the company reported below-expected results from a phase three trial for its CagriSema weight loss drug.The drug combines semaglutide, also… About the author:
Get involved!
Comments